A detailed history of Bell Investment Advisors, Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Bell Investment Advisors, Inc holds 26 shares of ARVN stock, worth $468. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26
Previous 26 -0.0%
Holding current value
$468
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$24.46 - $40.4 $269 - $444
11 Added 73.33%
26 $0
Q3 2023

Nov 08, 2023

SELL
$19.64 - $28.21 $314 - $451
-16 Reduced 51.61%
15 $0
Q2 2023

Aug 09, 2023

SELL
$21.73 - $31.43 $347 - $502
-16 Reduced 34.04%
31 $0
Q1 2023

May 10, 2023

BUY
$26.15 - $37.26 $1,229 - $1,751
47 New
47 $1,000
Q2 2022

Aug 12, 2022

SELL
$36.01 - $74.24 $324 - $668
-9 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $658 - $970
9 New
9 $1,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $958M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Bell Investment Advisors, Inc Portfolio

Follow Bell Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bell Investment Advisors, Inc with notifications on news.